@article{8764,
  keywords = {Humans, Leprostatic Agents, leprosy},
  author = {Worobec SM},
  title = {Treatment of leprosy/Hansen's disease in the early 21st century.},
  abstract = {<p>Leprosy, or Hansen's disease (HD), is caused by Mycobacterium leprae, a slowly dividing mycobacterium that has evolved to be an intracellular parasite, causing skin lesions and nerve damage. Less than 5% of people exposed to M. leprae develop clinical disease. Host cell-mediated resistance determines whether an individual will develop paucibacillary or multibacillary disease. Hansen's disease is a worldwide disease with about 150 new cases reported annually in the United States. Effective anti-mycobacterial treatments are available, and many patients experience severe reversal and erythema nodosum leprosum reactions that also require treatment. Leprosy has been the target of a World Health Organization multiple drug therapy campaign to eliminate it as a national public health problem in member countries, but endemic regions persist. In the United States, the National Hansen's Disease Program has primary responsibility for medical care, research, and information.</p>},
  year = {2009},
  journal = {Dermatologic therapy},
  volume = {22},
  pages = {518-37},
  month = {2009 Nov-Dec},
  issn = {1529-8019},
  doi = {10.1111/j.1529-8019.2009.01274.x},
  language = {eng},
}